Page 13 - நிர்வகித்தல் அறிவியல் ஆசிரியர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

#AANAM – Blacks, Whites Respond Differently to B-cell Targeting MS Therapies

team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests. “While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to have more severe courses of MS,” llya Kister, MD, said in a press release. Kister, of the NYU Grossman School of Medicine in New York, is the study’s senior author and a fellow of the American Academy of Neurology.

New yorkUnited statesMarta figueiredoLucia saidenbergUniversity of lisbonGrossman school of medicineAmerican academy of neurology annual meetingAmerican academy of neurologyBiomedical sciencesNyu ms care centerMultiple sclerosis news todayteamAfrican americanAmerican academyEmerging science sessionNeurology annual meetingMolecular biology

Novartis Kesimpta for Relapsing MS Approved in UK as At-home Therapy

4.6 (8) Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease. More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans. This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland, Singapore, Australia, Japan, Argentina, the United Arab Emirates, Albania, and India. The U.K.’s National Institute for Health Care and Excellence (NICE) and the Scottish Medicines Consortium now will decide whether to add Kesimpta to their respective National Health Service (NHS), which would allow patients to access treatments at low or no cost. NICE’s decision is

New yorkUnited statesUnited kingdomUnited arab emiratesColumbia universitySanofi genzymeDavid martinOwen pearsonChinmay bhattUniversity of lisbonDepartment of microbiology immunologyBiomedical sciencesNational health serviceUk national institute for health careHealthcare products regulatory agencyLaboratory of doctor davida fidock

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS 4.8 (5) Interim data from a Phase 2 trial of Immunic Therapeutics’ investigational oral therapy IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis (RRMS) patients has established a once-daily, 30 mg dose as the most appropriate for future Phase 3 trials. The company is now in discussions with regulatory authorities, including those in the U.S. and Europe, regarding pivotal Phase 3 testing expected to start later this year. At the request of the U.S. Food and Drug Administration (FDA), Immunic will directly submit an investigational new drug (IND) application for the right to open a Phase 3 trial, instead of waiting for an end-of-Phase 2 meeting, it reported in a press release.

Andreas muehlerDaniel vittUniversity of torontoUniversity of lisbonDrug administrationBiomedical sciencesImmunic therapeuticMolecular biologyUniversidade nova de lisboaManaging science editorடேனியல் விட்பல்கலைக்கழகம் ஆஃப் டொராண்டோபல்கலைக்கழகம் ஆஃப் லிஸ்பன்உயிர் மருத்துவ அறிவியல்மூலக்கூறு உயிரியல்யுனிவர்சிடேட் நோவா டி லிஸ்போவா

Harvard Professor Wins Dystel Prize for Work on MS Immune Mechanisms

Harvard Professor Wins Dystel Prize for Work on MS Immune Mechanisms
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesOscar dystelJohn jay dystelHoward weinerBruce beboVijay kuchrooUniversity of torontoUniversity of lisbonMs societyNational ms societyAmerican academy of neurologyHarvard medical schoolBiomedical sciencesDystel prizeAmerican academyMolecular biology

Ocrevus Use Linked to PML in Man, 78, With PPMS, Case Report Says

Ocrevus Use Linked to PML in Man, 78, With PPMS, Case Report Says
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesOcrelizumab monotherapyUniversity of torontoShore university hospitalUniversity of lisbonBiomedical sciencesMultifocal leukoencephalopathyNorth shore university hospitalMolecular biologyUniversidade nova de lisboaManaging science editorபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்பல்கலைக்கழகம் ஆஃப் டொராண்டோகரை பல்கலைக்கழகம் மருத்துவமனை